These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9428916)

  • 1. A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients.
    Michelotti A; Salvadori B; Donati S; Tognoni A; Tibaldi C; Conte PF
    Tumori; 1997; 83(5):826-8. PubMed ID: 9428916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study.
    Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L
    Tumori; 1998; 84(6):659-61. PubMed ID: 10080671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
    Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
    Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I; Keefe D; Myers M; Caruso D
    Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors.
    Frustaci S; Buonadonna A; Romanini A; Comandone A; Dalla Palma M; Gamucci T; Verusio C; Lionetto R; Dani C; Casali P; Santoro A
    Tumori; 1999; 85(4):229-33. PubMed ID: 10587022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
    Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J
    Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil.
    Lauro VD; Spazzapan S; Lombardi D; Paolello C; Scuderi C; Crivellari D; Magri MD; Veronesi A
    Tumori; 2001; 87(1):27-9. PubMed ID: 11669554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
    Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A
    Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
    Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
    Campisi C; Fabi A; Papaldo P; Tomao S; Massidda B; Zappala A; Ionta MT; Cognetti F
    Ann Oncol; 1998 May; 9(5):565-7. PubMed ID: 9653499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
    Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
    J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.